- Home
- BEAG vs TSHA Comparison
BEAG vs TSHA Comparison
Compare BEAG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAG
- TSHA
- Stock Information
- Founded
- BEAG 2021
- TSHA 2019
- Country
- BEAG United States
- TSHA United States
- Employees
- BEAG N/A
- TSHA N/A
- Industry
- BEAG
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- BEAG
- TSHA Health Care
- Exchange
- BEAG NYSE
- TSHA Nasdaq
- Market Cap
- BEAG 317.4M
- TSHA 397.8M
- IPO Year
- BEAG 2024
- TSHA 2020
- Fundamental
- Price
- BEAG $10.40
- TSHA $2.10
- Analyst Decision
- BEAG
- TSHA Strong Buy
- Analyst Count
- BEAG 0
- TSHA 8
- Target Price
- BEAG N/A
- TSHA $6.63
- AVG Volume (30 Days)
- BEAG 165.1K
- TSHA 2.9M
- Earning Date
- BEAG 01-01-0001
- TSHA 05-16-2025
- Dividend Yield
- BEAG N/A
- TSHA N/A
- EPS Growth
- BEAG 144.20
- TSHA N/A
- EPS
- BEAG 0.21
- TSHA N/A
- Revenue
- BEAG N/A
- TSHA $8,333,000.00
- Revenue This Year
- BEAG N/A
- TSHA N/A
- Revenue Next Year
- BEAG N/A
- TSHA N/A
- P/E Ratio
- BEAG $49.81
- TSHA N/A
- Revenue Growth
- BEAG N/A
- TSHA N/A
- 52 Week Low
- BEAG $9.84
- TSHA $1.05
- 52 Week High
- BEAG $11.20
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- BEAG N/A
- TSHA 58.01
- Support Level
- BEAG N/A
- TSHA $1.85
- Resistance Level
- BEAG N/A
- TSHA $2.73
- Average True Range (ATR)
- BEAG 0.00
- TSHA 0.27
- MACD
- BEAG 0.00
- TSHA 0.04
- Stochastic Oscillator
- BEAG 0.00
- TSHA 58.47
About BEAG BOLD EAGLE ACQUISITION CORP
Bold Eagle Acquisition Corp is a blank check company.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.